Washington, D.C. 20549



Pursuant to Section 13 or 15(D)

of the Securities Exchange Act of 1934

September 21, 2020

Date of report (Date of earliest event reported)

Agile Therapeutics, Inc.

(Exact name of registrant as specified in its charter)




(State or other jurisdiction
of incorporation)


File Number)

(IRS Employer

Identification No.)

101 Poor Farm Road

Princeton, New Jersey

(Address of principal executive offices)


(Zip Code)

Registrant's telephone number, including area code (609) 683-1880

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class

Trading Symbol(s)

Name of each exchange on which registered

Common stock, par value $0.0001 per share


The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter)

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 7.01. Regulation FD Disclosure.

On September 21, 2020, Agile Therapeutics, Inc. (the “Company”) hosted an analyst day presentation (“Analyst Day”). Members of the Company’s executive team discussed launch and commercialization plans for Twirla®, the Company’s once weekly low-dose prescription contraceptive patch. Management was joined by a leading external expert who provided clinical perspectives on Twirla, as well as insights into today’s contraceptive marketplace.

During the presentation, the Company reaffirmed its previously announced operating expense guidance for the full year 2020 to be in the range of $52 million to $56 million and its previously announced net revenue guidance for the fourth quarter of 2020 to be in the range of $1 million to $2 million. The Company also reaffirmed its belief that, based on the Company’s current business plan and ability to launch Twirla, its cash, cash equivalents and marketable securities as of June 30, 2020 will be sufficient to meet its projected operating requirements through the end of 2021. If the COVID-19 pandemic or other factors impact the Company’s current business plans or its ability to generate revenue from the launch of Twirla, the Company believes it has the ability to revise its commercial plans, including curtailing sales and marketing spending, to allow it to continue to fund its operations.

A live webcast of the Analyst Day as well as the presentation materials for the event were simultaneously made accessible through the Investor Relations section of the Company’s website. A replay of the webcast and the presentation materials are available at https://ir.agiletherapeutics.com/. The replay will be accessible for the next 30 days.

In accordance with General Instructions B.2 and B.6 of Form 8-K, the information included in this Current Report on Form 8-K, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Exchange Act or Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.


Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Agile Therapeutics, Inc.

Dated: September 21, 2020


/s/ Alfred Altomari


Alfred Altomari


Chairman and Chief Executive Officer